Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada.

He J, Bowen JM, Xie F, Goeree R.

Value Health. 2012 Sep-Oct;15(6):894-906. doi: 10.1016/j.jval.2012.06.005. Epub 2012 Aug 9. Review.

2.

Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Dakin H, Sherman M, Fung S, Fidler C, Bentley A.

Pharmacoeconomics. 2011 Dec;29(12):1075-91. doi: 10.2165/11589260-000000000-00000.

PMID:
22077579
3.

Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.

Wu B, Li T, Chen H, Shen J.

Value Health. 2010 Aug;13(5):592-600. doi: 10.1111/j.1524-4733.2010.00733.x. Epub 2010 Apr 30.

4.

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

Buti M, Brosa M, Casado MA, Rueda M, Esteban R.

J Hepatol. 2009 Oct;51(4):640-6. doi: 10.1016/j.jhep.2009.04.013. Epub 2009 May 20.

PMID:
19576651
5.

Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.

Zhang C, Ke W, Gao Y, Zhou S, Liu L, Ye X, Yao Z, Yang Y.

Clin Drug Investig. 2015 Mar;35(3):197-209. doi: 10.1007/s40261-015-0273-y.

PMID:
25672930
6.

A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

Spackman DE, Veenstra DL.

Pharmacoeconomics. 2008;26(11):937-49.

PMID:
18850763
7.

Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.

Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H.

Value Health. 2015 Sep;18(6):800-9. doi: 10.1016/j.jval.2015.05.007. Epub 2015 Jul 27.

8.

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG.

Pharmacoeconomics. 2007;25(11):963-77.

PMID:
17960954
9.

Entecavir for the treatment of chronic hepatitis B infection.

Shepherd J, Gospodarevskaya E, Frampton G, Cooper K.

Health Technol Assess. 2009 Oct;13 Suppl 3:31-6. doi: 10.3310/hta13suppl3/05. Review.

10.

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.

Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y.

BMC Health Serv Res. 2014 Apr 14;14:170. doi: 10.1186/1472-6963-14-170.

11.

Economic evaluation of treatments for chronic hepatitis B.

Wiens A, Lenzi L, Venson R, Pedroso ML, Correr CJ, Pontarolo R.

Braz J Infect Dis. 2013 Jul-Aug;17(4):418-26. doi: 10.1016/j.bjid.2012.12.005. Epub 2013 Jul 10. Review.

12.

Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.

Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, Zhou S, Yang Y.

Hepatol Int. 2016 Nov;10(6):924-936. Epub 2016 Jun 7.

PMID:
27271357
13.

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

Arnold E, Yuan Y, Iloeje U, Cook G.

Appl Health Econ Health Policy. 2008;6(4):231-46. doi: 10.2165/00148365-200806040-00005.

PMID:
19382822
14.

Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.

Almeida AM, da Silva AL, Cherchiglia ML, Andrade EI, de Oliveira GL, Acurcio Fde A.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S24-8. doi: 10.1016/j.jval.2011.05.011.

15.

Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.

Oliveira GL, Almeida AM, Silva AL, Brandão CM, Andrade EI, Cherchiglia ML, Acurcio Fde A.

Rev Saude Publica. 2013 Aug;47(4):769-78; discussion 779. doi: 10.1590/S0034-8910.2013047004529. English, Portuguese.

16.
17.

Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.

Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y.

Clin Drug Investig. 2017 Mar;37(3):233-247. doi: 10.1007/s40261-016-0486-8.

PMID:
27928739
18.

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.

Lui YY, Tsoi KK, Wong VW, Kao JH, Hou JL, Teo EK, Mohamed R, Piratvisuth T, Han KH, Mihm U, Wong GL, Chan HL.

Antivir Ther. 2010;15(2):145-55. doi: 10.3851/IMP1496.

PMID:
20386069
19.

Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.

Lee KK, Wu DB, Chow PY, Lee VW, Li H.

J Gastroenterol Hepatol. 2012 Jul;27(7):1167-74. doi: 10.1111/j.1440-1746.2011.07047.x.

PMID:
22141402
20.

Telbivudine for the treatment of chronic hepatitis B infection.

Hartwell D, Jones J, Harris P, Cooper K.

Health Technol Assess. 2009 Oct;13 Suppl 3:23-30. doi: 10.3310/hta13suppl3/04. Review.

Supplemental Content

Support Center